Francesco Bertolini

List of Publications by Year
in descending order

245 papers	12,007 citations	25014 57 h-index	30894 102 g-index
256 all docs	256 docs citations	256 times ranked	12759 citing authors

#	Article	IF	Citations
1	Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1). Scientific Reports, 2022, 12, 1341.	1.6	11
2	The metabolism of cells regulates their sensitivity to NK cells depending on p53 status. Scientific Reports, 2022, 12, 3234.	1.6	14
3	A single-cell transcriptomic landscape of innate and adaptive intratumoral immunity in triple negative breast cancer during chemo- and immunotherapies. Cell Death Discovery, 2022, 8, 106.	2.0	10
4	Hematological disorders after salvage <scp>PARPi</scp> treatment for ovarian cancer: Cytogenetic and molecular defects and clinical outcomes. International Journal of Cancer, 2022, 151, 1791-1803.	2.3	7
5	Cyclophosphamide and Vinorelbine Activate Stem-Like CD8+ T Cells and Improve Anti-PD-1 Efficacy in Triple-Negative Breast Cancer. Cancer Research, 2021, 81, 685-697.	0.4	31
6	Clinical presentation, diagnosis and management of therapyâ€related hematological disorders in women with epithelial ovarian cancer treated with chemotherapy and polyâ€ADPâ€ribose polymerase inhibitors: A singleâ€center experience. International Journal of Cancer, 2021, 148, 170-177.	2.3	9
7	Cellular and Molecular Players in the Interplay between Adipose Tissue and Breast Cancer. International Journal of Molecular Sciences, 2021, 22, 1359.	1.8	5
8	Archaeogenomic distinctiveness of the Isthmo-Colombian area. Cell, 2021, 184, 1706-1723.e24.	13.5	30
9	Drug Repurposing in Oncology, an Attractive Opportunity for Novel Combinatorial Regimens. Current Medicinal Chemistry, 2021, 28, 2114-2136.	1.2	6
10	A â€œtwo-hitâ€•(chemo)therapy to improve checkpoint inhibition in cancer. Oncoscience, 2021, 8, 55-57.	0.9	3
11	Abstract 1653: A single-cell atlas of the effect of chemotherapeutics over intratumoral immune cells reveals that combining an alkylating agent and a vinca alkaloid can activate antigen presenting cells and increase tcf1+ stem-like CD8+ T-cells, thus improving anti-PD-1 efficacy in triple negative breast cancer and lymphoma. , 2021, , .		0
12	The Dual Role of Innate Lymphoid and Natural Killer Cells in Cancer. from Phenotype to Single-Cell Transcriptomics, Functions and Clinical Uses. Cancers, 2021, 13, 5042.	1.7	7
13	New Insight to Overcome Tumor Resistance: An Overview from Cellular to Clinical Therapies. Life, 2021, 11, 1131.	1.1	3
14	SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial. Blood, 2021, 138, 3436-3436.	0.6	2
15	Circulating endothelial progenitors are increased in COVIDâ€19 patients and correlate with SARSâ€CoVâ€2 RNA in severe cases. Journal of Thrombosis and Haemostasis, 2020, 18, 2744-2750.	1.9	39
16	Denatonium as a Bitter Taste Receptor Agonist Modifies Transcriptomic Profile and Functions of Acute Myeloid Leukemia Cells. Frontiers in Oncology, 2020, 10, 1225.	1.3	14
17	Plant TDP1 (Tyrosyl-DNA Phosphodiesterase 1): A Phylogenetic Perspective and Gene Expression Data Mining. Genes, 2020, 11, 1465.	1.0	2
18	Efficacy of venetoclax based salvage chemotherapy followed by â€œMinimal Residual Disease drivenâ€•venetoclax maintenance therapy post-allotransplant in a young patient with high risk primary refractory acute myeloid leukemia. Leukemia and Lymphoma, 2020, 61, 2277-2279.	0.6	4

#	Article	IF	Citations
19	Red cellâ€“bound antibodies and transfusion requirements in hospitalized patients with COVID-19. Blood, 2020, 136, 766-768.	0.6	60
20	The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs. Haematologica, 2020, 105, 2420-2431.	1.7	12
21	Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside. European Journal of Cancer, 2019, 122, 22-41.	1.3	7
22	Identifying Drug Repurposing Opportunities in Oncology. Cancer Journal (Sudbury, Mass), 2019, 25, 82-87.	1.0	8
23	Desperately seekingâ€¦Models to find the right partner and the best use for checkpoint inhibitors. British Journal of Cancer, 2019, 120, 139-140.	2.9	2
24	Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. Haematologica, 2019, 104, 729-737.	1.7	58
25	Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features. Blood, 2019, 134, 5414-5414.	0.6	0
26	Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. British Journal of Cancer, 2018, 118, 1329-1336.	2.9	75
27	Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cellsâ€™ vulnerability to DNA-damaging agents. Haematologica, 2018, 103, 80-90.	1.7	48
28	The E3 ubiquitin ligase WWP1 sustains the growth of acute myeloid leukaemia. Leukemia, 2018, 32, 911-919.	3.3	34
29	Stromal Cell-Derived Factor-1Î± Promotes Endothelial Colony-Forming Cell Migration Through the Ca²⁺-Dependent Activation of the Extracellular Signal-Regulated Kinase 1/2 and Phosphoinositide 3-Kinase/AKT Pathways. Stem Cells and Development, 2018, 27, 23-34.	1.1	41
30	Mitochondrial Complex I activity signals antioxidant response through ERK5. Scientific Reports, 2018, 8, 7420.	1.6	38
31	Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors. Theranostics, 2018, 8, 3856-3869.	4.6	48
32	Changes in metabolism affect expression of ABC transporters through ERK5 and depending on p53 status. Oncotarget, 2018, 9, 1114-1129.	0.8	22
33	A Cellular Therapy with Haploidentical Peripheral Hematopoietic STEM CELL Transplantation MAY be a Therapeutic Option in Patients with Relapsed Lymphoma with Chemorefractory Disease. Blood, 2018, 132, 2189-2189.	0.6	0
34	Blocking Surgically Induced Lysyl Oxidase Activity Reduces the Risk of Lung Metastases. Cell Reports, 2017, 19, 774-784.	2.9	82
35	Fat Grafting after Invasive Breast Cancer: A Matched Case-Control Study. Plastic and Reconstructive Surgery, 2017, 139, 1292-1296.	0.7	70
36	P2.01-044 Baseline Peripheral Blood Cell Subsets Associated with Survival Outcomes in Advanced NSCLC Treated with Nivolumab in Second-Line Setting. Journal of Thoracic Oncology, 2017, 12, S812.	0.5	1

#	Article	IF	Citations
37	The PDK1 Inhibitor Dichloroacetate Controls Cholesterol Homeostasis Through the ERK5/MEF2 Pathway. Scientific Reports, 2017, 7, 10654.	1.6	23
38	Adipose Progenitor Cell Secretion of GM-CSF and MMP9 Promotes a Stromal and Immunological Microenvironment That Supports Breast Cancer Progression. Cancer Research, 2017, 77, 5169-5182.	0.4	60
39	GM-CSF promotes a supportive adipose and lung microenvironment in metastatic breast cancer. Oncoscience, 2017, 4, 126-127.	0.9	8
40	Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells. Oncotarget, 2017, 8, 5895-5908.	0.8	45
41	Roles of obesity in the development and progression of breast cancer. Discovery Medicine, 2017, 24, 183-190.	0.5	5
42	Next generation metronomic chemotherapyâ€"report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6â€"8 May 2016, Mumbai. Ecancermedicalscience, 2016, 10, 689.	0.6	10
43	A Phase I Study of the Anti-Activin Receptor-Like Kinase 1 (ALK-1) Monoclonal Antibody PF-03446962 in Patients with Advanced Solid Tumors. Clinical Cancer Research, 2016, 22, 2146-2154.	3.2	26
44	A Combinatorial Investigation of the Response to Anti-angiogenic Therapy in Breast Cancer: New Strategies for Patient Selection and Opportunities for Reconsidering Anti-VEGF, Anti-PI3K and Checkpoint Inhibition. EBioMedicine, 2016, 10, 13-14.	2.7	4
45	Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. Scientific Reports, 2016, 6, 18673.	1.6	46
46	Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) Production. EBioMedicine, 2016, 3, 43-53.	2.7	41
47	Characterization of Cancer Stem Cells. Methods in Molecular Biology, 2016, 1464, 49-62.	0.4	13
48	The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia. Scientific Reports, 2015, 5, 18137.	1.6	28
49	Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma â€" a case report. Scientific Reports, 2015, 5, 14829.	1.6	2
50	Lung Cancer Onset in Wild Type Mice Following Bone Marrow Reconstitution with krasv12 Cells. Scientific Reports, 2015, 5, 13047.	1.6	1
51	Lessons from the first ecancer symposium on angiogenesis in gastric cancer. Ecancermedicalscience, 2015, 9, 553.	0.6	0
52	Biomarkers of cancer angioprevention for clinical studies. Ecancermedicalscience, 2015, 9, 600.	0.6	6
53	Stem cells from adipose tissue and breast cancer: hype, risks and hope. British Journal of Cancer, 2015, 112, 419-423.	2.9	81
54	The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias. Molecular Cancer Therapeutics, 2015, 14, 889-898.	1.9	30

#	Article	IF	Citations
55	Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. Breast, 2015, 24, 263-271.	0.9	13
56	Safety of Lipofilling in Patients with Breast Cancer. Clinics in Plastic Surgery, 2015, 42, 339-344.	0.7	40
57	Drug repurposing in oncologyâ€"patient and health systems opportunities. Nature Reviews Clinical Oncology, 2015, 12, 732-742.	12.5	247
58	The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. International Journal of Cancer, 2015, 136, E534-44.	2.3	119
59	The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism. Oncotarget, 2015, 6, 19228-19245.	0.8	28
60	P2X7 Receptor Activation By ATP As Target of Novel Therapies in Acute Myeloid Leukemia. Blood, 2015, 126, 3684-3684.	0.6	0
61	Mechanisms of obesity in the development of breast cancer. Discovery Medicine, 2015, 20, 121-8.	0.5	14
62	ecancermedicalscience. Ecancermedicalscience, 2014, 8, 463.	0.6	26
63	Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis, 2014, 35, 1055-1066.	1.3	118
64	About CD45â˜'/CD31+/CD105+ Circulating Cells in Patients with Gynecologic Malignanciesâ€"Letter. Clinical Cancer Research, 2014, 20, 1393-1393.	3.2	0
65	Obesity, proinflammatory mediators, adipose tissue progenitors, and breast cancer. Current Opinion in Oncology, 2014, 26, 545-550.	1.1	15
66	Metronomic Chemotherapy in Breast Cancers. , 2014, , 93-110.		2
67	A Subpopulation of Circulating Endothelial Cells Express CD109 and is Enriched in the Blood of Cancer Patients. PLoS ONE, 2014, 9, e114713.	1.1	17
68	Adipose tissue and breast cancer progression: A link between metabolism and cancer. Breast, 2013, 22, S48-S49.	0.9	20
69	Contribution of endothelial precursors of adipose tissue to breast cancer: Progression-link with fat graft for reconstructive surgery. Annales D'Endocrinologie, 2013, 74, 106-107.	0.6	10
70	Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. Drug Discovery Today, 2013, 18, 193-201.	3.2	57
71	Evaluation of fat grafting safety in patients with intra epithelial neoplasia: a matched-cohort study. Annals of Oncology, 2013, 24, 1479-1484.	0.6	172
72	Complementary Populations of Human Adipose CD34+ Progenitor Cells Promote Growth, Angiogenesis, and Metastasis of Breast Cancer. Cancer Research, 2013, 73, 5880-5891.	0.4	91

#	Article	IF	Citations
73	On the clinical relevance of circulating endothelial cells and platelets in prostate cancer. British Journal of Cancer, 2013, 108, 1387-1387.	2.9	4
74	Definition of miRNAs Expression Profile in Glioblastoma Samples: The Relevance of Non-Neoplastic Brain Reference. PLoS ONE, 2013, 8, e55314.	1.1	22
75	Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan. PLoS ONE, 2013, 8, e74345.	1.1	28
76	Trafficking of Cells from Adipose Tissue to Tumor Microenvironment. , 2013, , 147-163.		0
77	Lenalidomide for Multiple Myeloma. New England Journal of Medicine, 2012, 367, 573-575.	13.9	4
78	Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts. Laboratory Investigation, 2012, 92, 952-966.	1.7	65
79	Locoregional recurrence risk after lipofilling in breast cancer patients. Annals of Oncology, 2012, 23, 582-588.	0.6	203
80	Amelioration of Glucose Control Mobilizes Circulating Pericyte Progenitor Cells in Type 2 Diabetic Patients with Microangiopathy. Experimental Diabetes Research, 2012, 2012, 1-8.	3.8	13
81	Spontaneous Cell Fusion of Acute Leukemia Cells and Macrophages Observed in Cells with Leukemic Potential. Neoplasia, 2012, 14, 1057-IN14.	2.3	24
82	The White Adipose Tissue Used in Lipotransfer Procedures Is a Rich Reservoir of CD34+ Progenitors Able to Promote Cancer Progression. Cancer Research, 2012, 72, 325-334.	0.4	138
83	miRNAs Expression Analysis in Paired Fresh/Frozen and Dissected Formalin Fixed and Paraffin Embedded Glioblastoma Using Real-Time PCR. PLoS ONE, 2012, 7, e35596.	1.1	34
84	Metronomic Chemotherapy Combined With Bevacizumab and Erlotinib in Patients With Metastatic HER2-Negative Breast Cancer: Clinical and Biological Activity. Clinical Breast Cancer, 2012, 12, 207-214.	1.1	59
85	Adipose tissue cells, lipotransfer and cancer: A challenge for scientists, oncologists and surgeons. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 209-214.	3.3	45
86	Increased mean corpuscular volume of red blood cells predicts response to metronomic capecitabine and cyclophosphamide in combination with bevacizumab. Breast, 2012, 21, 309-313.	0.9	25
87	Circulating Endothelial Cells and Circulating Endothelial Progenitors. Recent Results in Cancer Research, 2012, 195, 163-170.	1.8	14
88	Plasma levels of IL-8 and g-CSF in high-grade gliomas treated with bevacizumab.. Journal of Clinical Oncology, 2012, 30, 2083-2083.	0.8	5
89	Human Haemato-Endothelial Precursors: Cord Blood CD34+ Cells Produce Haemogenic Endothelium. PLoS ONE, 2012, 7, e51109.	1.1	23
90	Evaluation of Circulating Endothelial Precursor Cells in Cancer Patients. Methods in Molecular Biology, 2012, 904, 165-172.	0.4	9

#	Article	IF	Citations
91	Circulating endothelial cells as biomarkers for patients receiving bevacizumab. Lancet Oncology, The, 2011, 12, 217-218.	5.1	4
92	Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. Diabetes, Obesity and Metabolism, 2011, 13, 718-725.	2.2	50
93	In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levels. Leukemia, 2011, 25, 733-736.	3.3	23
94	Response to anti-angiogenesis: An ever changing feature. Breast, 2011, 20, S61-S62.	0.9	2
95	Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer. Drug Discovery Today, 2011, 16, 1052-1060.	3.2	35
96	Circulating perivascular progenitors: A target of PDGFR inhibition. International Journal of Cancer, 2011, 129, 1344-1350.	2.3	21
97	Therapeutic Effect of Lenalidomide in a Novel Xenograft Mouse Model of Human Blastic NK Cell Lymphoma/Blastic Plasmacytoid Dendritic Cell Neoplasm. Clinical Cancer Research, 2011, 17, 6163-6173.	3.2	33
98	Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies. Cancer Research, 2011, 71, 1362-1373.	0.4	117
99	Host Response to Short-term, Single-Agent Chemotherapy Induces Matrix Metalloproteinase-9 Expression and Accelerates Metastasis in Mice. Cancer Research, 2011, 71, 6986-6996.	0.4	102
100	International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). Journal of the National Cancer Institute Monographs, 2011, 2011, 147-151.	0.9	61
101	Evidence of Distinct Tumour-Propagating Cell Populations with Different Properties in Primary Human Hepatocellular Carcinoma. PLoS ONE, 2011, 6, e21369.	1.1	56
102	Anti-angiogenesis in cancer; met and unmet goals - an interview with Robert Kerbel. International Journal of Developmental Biology, 2011, 55, 395-398.	0.3	4
103	CD45-CD34+ Endothelial Progenitor Cells (EPCs) from Human Adipose Tissue Promote Tumor Growth and Metastases. Blood, 2011, 118, 2208-2208.	0.6	0
104	Mature Circulating Endothelial Cells and Progenitors in Patients with Chronic Gvhd. Blood, 2011, 118, 4700-4700.	0.6	0
105	Simultaneous characterization of progenitor cell compartments in adult human liver. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 31-40.	1.1	8
106	Sex-related efficiency in NSG mouse engraftment. Blood, 2010, 116, 2616-2617.	0.6	16
107	If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma. BMC Cancer, 2010, 10, 644.	1.1	20
108	Cellular and soluble markers of tumor angiogenesis: From patient selection to the identification of the most appropriate postresistance therapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 2010, 1806, 131-137.	3.3	12

#	Article	IF	Citations
109	Expression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by WaldenstrÃ¶m's Macroglobulinemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2â€²-deoxyadenosine (2-CdA) and Rituximab. Leukemia Research, 2010, 34, 454-457.	0.4	12
110	Blood-Based Biomarkers for the Optimization of Anti-Angiogenic Therapies. Cancers, 2010, 2, 1027-1039.	1.7	1
111	Miniaturized FISH for screening of onco-hematological malignancies. BioTechniques, 2010, 49, 497-504.	0.8	39
112	Rituximab and Subcutaneous 2-Chloro-2â€²-Deoxyadenosine Combination Treatment for Patients With WaldenstrÃ¶m Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter Study. Journal of Clinical Oncology, 2010, 28, 2233-2238.	0.8	56
113	Î¶â€Crystallin is a bclâ€2 mRNA binding protein involved inbclâ€2overexpression in Tâ€cell acute lymphocytic leukemia. FASEB Journal, 2010, 24, 1852-1865.	0.2	24
114	Angiogenic cells, macroparticles and RNA transcripts in laparoscopic vs open surgery for colorectal cancer. Cancer Biology and Therapy, 2010, 10, 682-685.	1.5	9
115	Circulating endothelial cells as biomarkers in clinical oncology. Microvascular Research, 2010, 79, 224-228.	1.1	50
116	EPO Receptor Gain-of-Function Causes Hereditary Polycythemia, Alters CD34+ Cell Differentiation and Increases Circulating Endothelial Precursors. PLoS ONE, 2010, 5, e12015.	1.1	23
117	Impact of Endothelial Progenitor Cells on Tumor Angiogenesis and Outcome of Antiangiogenic Therapy: New Perspectives on an Ongoing Controversy. , 2010, , 257-273.		0
118	Circulating endothelial cells as biomarkers for angiogenesis in tumor progression. Frontiers in Bioscience - Scholar, 2009, S1, 304-318.	0.8	13
119	Safety, Tolerability and Biological Effects of Long-Term Metronomic Administration of Non-Cytotoxic Anti-Angiogenic Agents. Oncology, 2009, 77, 358-365.	0.9	9
120	Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents. Cancer Research, 2009, 69, 7524-7528.	0.4	78
121	Quantification of Circulating Endothelial Cells by Flow Cytometry. Clinical Cancer Research, 2009, 15, 3640-3640.	3.2	1
122	Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. Clinical Cancer Research, 2009, 15, 7652-7657.	3.2	102
123	The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer. Biochimica Et Biophysica Acta: Reviews on Cancer, 2009, 1796, 27-32.	3.3	22
124	Biomarkers for angiogenesis and antiangiogenic drugs in clinical oncology. Breast, 2009, 18, S48-S50.	0.9	4
125	Circulating endothelial cells (CECs) and progenitors (CEPs) in severe haemophiliacs with different clinical phenotype. British Journal of Haematology, 2009, 144, 803-805.	1.2	15
126	Validation of a Standardized Method for Enumerating Circulating Endothelial Cells and Progenitors: Flow Cytometry and Molecular and Ultrastructural Analyses. Clinical Cancer Research, 2009, 15, 267-273.	3.2	153

#	Article	IF	Citations
127	Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features. Anti-Cancer Drugs, 2009, 20, 197-203.	0.7	18
128	Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34â^' cell population with intrinsic resistance to imatinib. Blood, 2009, 114, 5191-5200.	0.6	62
129	Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells. Cancer and Metastasis Reviews, 2008, 27, 95-101.	2.7	15
130	Human acute leukemia cells injected in NOD/LtSzâ€‹scid/ILâ€2RÎ³ null mice generate a faster and more efficient disease compared to other NOD/scidâ€related strains. International Journal of Cancer, 2008, 123, 2222-2227.	2.3	155
131	Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. Leukemia Research, 2008, 32, 1628-1632.	0.4	1
132	Preoperative bevacizumab combined with letrozole and chemotherapy in locally advanced ER- and/or PgR-positive breast cancer: clinical and biological activity. British Journal of Cancer, 2008, 99, 1564-1571.	2.9	43
133	Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model. BJU International, 2008, 101, 884-888.	1.3	23
134	Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents. Cancer Cell, 2008, 14, 263-273.	7.7	424
135	Metronomic Cyclophosphamide and Capecitabine Combined With Bevacizumab in Advanced Breast Cancer. Journal of Clinical Oncology, 2008, 26, 4899-4905.	0.8	280
136	Circulating Endothelial Cell Number and Viability Are Reduced by Exposure to High Altitude. Endothelium: Journal of Endothelial Cell Research, 2008, 15, 53-58.	1.7	12
137	Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, E54; author reply E55.	3.3	51
138	The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification. Current Pharmaceutical Design, 2008, 14, 3780-3789.	0.9	8
139	Human acute leukemia cells injected in NOD/LtSz-scid/IL-2RÎ³ null mice generate a faster and more efficient disease compared to other NOD/scid-related strains. , 2008, 123, 2222.		1
140	Taxanes Induce a Rapid Mobilization of Different Populations of Circulating Endothelial Progenitors by SDF-1 Modulation in Cancer Patients.. Blood, 2008, 112, 1885-1885.	0.6	0
141	Molecular and Functional Analysis of Stem Cell Compartment of Chronic Myelogenous Leukemia Reveals the Presence of a CD34â^' cell Population with Intrinsic Resistance to IMATINIB Treatment. Blood, 2008, 112, 4221-4221.	0.6	0
142	IgG Antibodies against Human Cytomegalovirus Late Protein UL94 in the Pathogenesis of Scleroderma-Like Skin Lesions in Chronic Graft Versus Host Disease. Blood, 2008, 112, 1169-1169.	0.6	0
143	Metronomic Antiangiogenic Chemotherapy: Questions and Answers. , 2008, , 593-607.		0
144	Surrogate Markers of Angiogenesis. , 2008, , 795-808.		0

#	Article	IF	Citations
145	The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration. Blood, 2007, 109, 533-542.	0.6	93
146	Hepatocyte-conditioned medium sustains endothelial differentiation of human hematopoietic-endothelial progenitors. Hepatology, 2007, 45, 1218-1228.	3.6	12
147	Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma. Journal of Viral Hepatitis, 2007, 14, 133-139.	1.0	47
148	Molecular and cellular biomarkers for angiogenesis in clinical oncology. Drug Discovery Today, 2007, 12, 806-812.	3.2	84
149	Continuous Immuno-Chemotherapy Followed by High Dose and Autologous Cell Transplantation May Improve the Event-Free-Survival in Mantle Cell Lymphoma Patients. Experience at the European Institute of Oncology in Milan.. Blood, 2007, 110, 5116-5116.	0.6	0
150	Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood, 2006, 108, 452-459.	0.6	242
151	The prevalence and clinical implications of c-kit expression in plasma cell myeloma. Histopathology, 2006, 48, 529-535.	1.6	14
152	The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nature Reviews Cancer, 2006, 6, 835-845.	12.8	559
153	Peripheral T-lymphocyte subsets in patients treated with Rituximabâ€“Chlorambucil combination therapy for indolent NHL. Annals of Hematology, 2006, 85, 813-814.	0.8	8
154	On the Origin and Nature of Elevated Levels of Circulating Endothelial Cells After Treatment With a Vascular Disrupting Agent. Journal of Clinical Oncology, 2006, 24, 4040-4040.	0.8	18
155	High-Dose Celecoxib and Metronomic â€œLow-doseâ€•Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Nonâ€“Hodgkin's Lymphoma. Clinical Cancer Research, 2006, 12, 5190-5198.	3.2	106
156	Comparison of Three Different NOD/SCID-Related Strains in Preclinical Models of Acute Leukemia.. Blood, 2006, 108, 2361-2361.	0.6	0
157	SP4, a Novel Anti-Cyclin D1 Rabbit Monoclonal Antibody, Is a Highly Sensitive Probe for Identifying Mantle Cell Lymphomas Bearing the t(11;14)(q13;q32) Translocation. Applied Immunohistochemistry and Molecular Morphology, 2005, 13, 318-322.	0.6	14
158	Targeting VE-cadherin (while naked, and not engaged). Blood, 2005, 105, 4157-4157.	0.6	0
159	Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood, 2005, 106, 3058-3061.	0.6	252
160	Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis. Cancer Cell, 2005, 7, 101-111.	7.7	332
161	Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast, 2005, 14, 466-479.	0.9	84
162	Systemic Effects of Surgery: Quantitative Analysis of Circulating Basic Fibroblast Growth Factor (bFGF), Vascular Endothelial Growth Factor (VEGF) and Transforming Growth Factor Beta (TGF-Î²) in Patients with Breast Cancer Who Underwent Limited or Extended Surgery. Breast Cancer Research and Treatment, 2005, 93, 35-40.	1.1	59

#	Article	IF	Citations
163	The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence ofp63 gene amplification. Journal of Pathology, 2005, 206, 337-345.	2.1	39
164	Circulating endothelial cells. Thrombosis and Haemostasis, 2005, 93, 228-235.	1.8	337
165	Cellular and Molecular Surrogate Markers to Monitor Targeted and Non- Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose. Current Cancer Drug Targets, 2005, 5, 551-559.	0.8	48
166	Circulating Endothelial Progenitor Cells. New England Journal of Medicine, 2005, 353, 2613-2616.	13.9	16
167	Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. Leukemia and Lymphoma, 2005, 46, 1345-1351.	0.6	38
168	In Vitro and In Vivo Induction of Human Hematopoietic Stem Cell Migration by Extracellular UTP.. Blood, 2005, 106, 1730-1730.	0.6	0
169	Assessing Tumor Angiogenesis. Cancer Research, 2004, 64, 4373-4377.	0.4	83
170	Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining. Modern Pathology, 2004, 17, 1513-1520.	2.9	20
171	Tailored therapy of adult acute leukaemia in Jehovah's Witnesses: unjustified reluctance to treat. European Journal of Haematology, 2004, 72, 264-267.	1.1	20
172	Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. British Journal of Haematology, 2004, 124, 289-298.	1.2	26
173	Cyclin D3 immunoreactivity in follicular lymphoma is independent of the t(6;14)(p21.1;q32.3) translocation orcyclin D3 gene amplification and is correlated with histologic grade and Ki-67 labeling index. International Journal of Cancer, 2004, 112, 71-77.	2.3	16
174	Skeletal muscle differentiation potential of human adult bone marrow cells. Experimental Cell Research, 2004, 295, 66-78.	1.2	54
175	Autologous Peripheral Blood Stem Cell Transplantation for Myocardial Regeneration: A Novel Strategy for Cell Collection and Surgical Injection. Annals of Thoracic Surgery, 2004, 78, 1808-1812.	0.7	73
176	Mammaglobin Expression in Leukapheresis Products Is a Predictive Marker of Poor Prognosis in Women with High-Risk Breast Cancer. Clinical Cancer Research, 2004, 10, 6039-6046.	3.2	18
177	AGF will make you blush. Blood, 2004, 103, 3610-3611.	0.6	0
178	Extracellular nucleotides are potent stimulators of human hematopoietic stem cells in vitro and in vivo. Blood, 2004, 104, 1662-1670.	0.6	111
179	Extracellular UTP Affects In Vitro Migration and In Vivo Homing and Engraftment of CD34+ Hematopoietic Stem Cells.. Blood, 2004, 104, 4122-4122.	0.6	3
180	Lymphoma Cell Detection and Follow-Up in the Rituximab Era: Concordance between Flow Cytometry, Qualitative/Quantitative PCR and FISH in the Marrow and Blood from 647 Patients.. Blood, 2004, 104, 1376-1376.	0.6	0

#	Article	IF	Citations
181	Prognostic Value of BCL2 Determination in Follicular NHL Patients Treated with Alkylating Containing Regimen Alone or in Combination with Rituximab.. Blood, 2004, 104, 4629-4629.	0.6	0
182	Angiogenesis occurs in hairy cell leukaemia (HCL) and in NOD/SCID mice transplanted with the HCL line Bonna-12. British Journal of Haematology, 2003, 120, 695-698.	1.2	18
183	Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. British Journal of Haematology, 2003, 123, 271-277.	1.2	30
184	Functional and kinetic characterization of granulocyte colony-stimulating factor-primed CD34â˜' human stem cells. British Journal of Haematology, 2003, 123, 720-729.	1.2	12
185	Cyclin D3 Immunoreactivity in Gastrointestinal Stromal Tumors Is Independent of Cyclin D3 Gene Amplification and Is Associated with Nuclear p27 Accumulation. Modern Pathology, 2003, 16, 886-892.	2.9	22
186	Cell cycle regulators in multiple myeloma: Prognostic implications of p53 nuclear accumulation. Human Pathology, 2003, 34, 41-47.	1.1	19
187	Idarubicin Containing Regimen in Multiple Myeloma: Preliminary Results of a Pilot Study Using a Modified "TANDEM" Transplant Program. Leukemia and Lymphoma, 2003, 44, 299-302.	0.6	7
188	Strategies to Investigate Circulating Endothelial Cells in Cancer. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2003, 33, 503-506.	0.5	13
189	Circulating Endothelial Cells as a Novel Marker of Angiogenesis. Advances in Experimental Medicine and Biology, 2003, 522, 83-97.	0.8	82
190	Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clinical Cancer Research, 2003, 9, 377-82.	3.2	99
191	Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Research, 2003, 63, 4342-6.	0.4	375
192	Chimerism of the Transplanted Heart. New England Journal of Medicine, 2002, 346, 1410-1412.	13.9	23
193	Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings. Journal of Clinical Oncology, 2002, 20, 4169-4180.	0.8	361
194	Short- and long-term safety of the 2 Ã— 106 CD34+ cells/kg threshold for hematopoietic reconstitution after high-dose chemotherapy and peripheral blood progenitor cell support. Annals of Oncology, 2002, 13, 983-984.	0.6	2
195	In vitro and in vivo hematopoietic potential of human stem cells residing in muscle tissue. Experimental Hematology, 2002, 30, 905-914.	0.2	34
196	Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. British Journal of Haematology, 2002, 118, 817-820.	1.2	87
197	CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma. Cancer Research, 2002, 62, 3106-12.	0.4	166
198	Mosaic tumour blood vessels and high-dose chemotherapy for breast cancer. Lancet Oncology, The, 2001, 2, 595.	5.1	3

#	Article	IF	Citations
199	Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Annals of Oncology, 2001, 12, 987-990.	0.6	81
200	Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood, 2001, 97, 3658-3661.	0.6	401
201	Clinical relevance of microvessel density in laryngeal squamous cell carcinomas. International Journal of Cancer, 2001, 92, 666-670.	2.3	27
202	Adverse effects associated with extracorporeal photochemotherapy. Transfusion, 2000, 40, 121-121.	0.8	17
203	REPLY TO GUNSILIUS ET AL. British Journal of Haematology, 2000, 108, 662-663.	1.2	0
204	Inhibition of angiogenesis and induction of endothelial and tumor cell apoptosis by green tea in animal models of human high-grade non-Hodgkin's lymphoma. Leukemia, 2000, 14, 1477-1482.	3.3	44
205	The thin red line. Experimental Hematology, 2000, 28, 993-1000.	0.2	77
206	Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood, 2000, 96, 282-287.	0.6	84
207	Endostatin, an antiangiogenic drug, induces tumor stabilization after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood, 2000, 96, 282-287.	0.6	8
208	Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. British Journal of Haematology, 1999, 106, 504-509.	1.2	151
209	Angiogenesis in myelodysplastic syndromes. British Journal of Cancer, 1999, 81, 1398-1401.	2.9	260
210	Epithelial tumour cell detection and the unsolved problems of nested RT-PCR: a new sensitive one step method without false positive results. Bone Marrow Transplantation, 1998, 22, 693-698.	1.3	29
211	Effects of storage temperature and time on cord blood progenitor cells. Transfusion, 1998, 38, 615-617.	0.8	6
212	Hematopoietic progenitor cell collection and neoplastic cell contamination in breast cancer patients receiving chemotherapy plus granulocyte-colony stimulating factor (G-CSF) or G-CSF alone for mobilization. Annals of Oncology, 1998, 9, 913-916.	0.6	8
213	Placental-Blood Transplantation. New England Journal of Medicine, 1997, 336, 68-70.	13.9	7
214	Megakaryocytic Progenitors Can Be Generated Ex Vivo and Safely Administered to Autologous Peripheral Blood Progenitor Cell Transplant Recipients. Blood, 1997, 89, 2679-2688.	0.6	177
215	Multilineage Long-Term Engraftment Potential of Drug-Resistant Hematopoietic Progenitors. Blood, 1997, 90, 3027-3036.	0.6	32
216	A new â€˜two stepâ€™ procedure for 4.5 log depletion of T and B cells in allogeneic transplantation and of neoplastic cells in autologous transplantation. Bone Marrow Transplantation, 1997, 19, 615-619.	1.3	19

#	Article	IF	Citations
217	Role of tumor cells contaminating the graft in breast cancer recurrence after high-dose chemotherapy. Bone Marrow Transplantation, 1997, 20, 167-169.	1.3	17
218	Collection of circulating progenitor cells after epirubicin, paclitaxel and filgrastim in patients with metastatic breast cancer. British Journal of Cancer, 1997, 75, 1368-1372.	2.9	23
219	A multicenter inspection of the swirling phenomenon in platelet concentrates prepared in routine practice. Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion. Transfusion, 1996, 36, 128-132.	0.8	100
220	Functional and Morphological Characterization of Immunomagnetically Selected CD34⁺Hematopoietic Progenitor Cells. Stem Cells, 1996, 14, 430-438.	1.4	31
221	Gene Transfer-Mediated Generation of Drug-Resistant Hemopoiesis. Leukemia and Lymphoma, 1996, 21, 17-23.	0.6	3
222	The effect of interleukin-12 in ex-vivo expansion of human haemopoietic progenitors. British Journal of Haematology, 1995, 90, 935-938.	1.2	12
223	Comparative Study of Different Procedures for the Collection and Banking of Umbilical Cord Blood. Stem Cells and Development, 1995, 4, 29-36.	1.0	76
224	A multicenter evaluation of reproducibility of swirling in platelet concentrates. Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion. Transfusion, 1994, 34, 796-801.	0.8	71
225	Retrovirus-mediated transfer of the multidrug resistance gene into human haemopoietic progenitor cells. British Journal of Haematology, 1994, 88, 318-324.	1.2	39
226	STORAGE IN SYNTHETIC MEDIUM AND LEUKOâ€DEPLETION OF PLATELET CONCENTRATES. Vox Sanguinis, 1994, 67, 155-158.	0.7	4
227	In Vitro Assessment of the Quality of Stored Platelet Concentrates. Transfusion Medicine Reviews, 1994, 8, 29-36.	0.9	176
228	Role of Lactate in Platelet Storage Lesion. Vox Sanguinis, 1993, 65, 194-198.	0.7	31
229	PLATELET QUALITY AND REDUCTION OF HLA EXPRESSION IN ACIDâ€TREATED PLATELET CONCENTRATES. British Journal of Haematology, 1993, 83, 525-527.	1.2	10
230	White cell-reduced red cells prepared by filtration: a critical evaluation of current filters and methods for counting residual white cells. Transfusion, 1993, 33, 128-133.	0.8	52
231	Platelet concentrates from buffy coats: Improved conditions for preparation and evaluation in routine clinical use. Transfusion Science, 1993, 14, 41-46.	0.6	11
232	Umbilical Cord Blood Banking: Evaluation of the Collection Procedure and of CFU-GM Content. Stem Cells and Development, 1993, 2, 233-234.	1.0	7
233	Platelet Concentrates Stored in Synthetic Medium after Filtration. Vox Sanguinis, 1992, 62, 82-86.	0.7	20
234	Platelet quality after 15-day storage of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium. Transfusion, 1992, 32, 9-16.	0.8	51

#	Article	IF	Citations
235	Role of acetate during platelet storage in a synthetic medium. Transfusion, 1992, 32, 152-156.	0.8	70
236	Platelet Concentrates Stored in Synthetic Medium after Filtration. Vox Sanguinis, 1992, 62, 82-86.	0.7	19
237	Comparison of Platelet Activation and Membrane Glycoprotein Ib and IIbâ€IIIa Expression after Filtration through Three Different Leukocyte Removal Filters. Vox Sanguinis, 1990, 59, 201-204.	0.7	16
238	Removal of white cells from red cells by transfusion through a new filter. Transfusion, 1990, 30, 30-33.	0.8	71
239	Comparison of Platelet Activation and Membrane Glycoprotein Ib and IIb-IIIa Expression after Filtration through Three Different Leukocyte Removal Filters. Vox Sanguinis, 1990, 59, 201-204.	0.7	30
240	Leukocyte-Poor Blood Components: A Purer and Safer Transfusion Product for Recipients?. Transfusion Medicine Reviews, 1990, 4, 19-23.	0.9	16
241	Platelet concentrates prepared from pooled buffy-coats and stored in a glucose-free crystalloid medium. The Milan experience. Transfusion Science, 1990, 11, 357-362.	0.6	12
242	Evaluation of platelet concentrates prepared from buffy coats and stored in a glucose-free crystalloid medium. Transfusion, 1989, 29, 605-609.	0.8	101
243	The Risk of Acquiring Transfusionâ€Transmissible Infections. Vox Sanguinis, 1988, 55, 186-187.	0.7	1
244	Leukocyte depletion of red cell units at the bedside by transfusion through a new filter. Transfusion, 1987, 27, 402-405.	0.8	70
245	Preparation of Leukocyteâ€Free Platelets for Transfusion by Filtration through Cotton Wool. Vox Sanguinis, 1983, 44, 115-120.	0.7	48